Table 1.
Demographic, clinical characteristics, results of SARS-CoV-2 test, and neutralization antibody activities on admission of eleven patients stratified by severity.
| Characteristics | Overall patients, n = 11 | Moderate, n = 4 | Severe-to-critical, n = 7 | P-value |
|---|---|---|---|---|
| Age, median, years | 78 | 59.5 | 83 | .13 |
| Sex | ||||
| Male, n (%) | 3 (27.3) | 1 (25.0) | 2 (28.6) | 1 |
| Comorbidities, n (%) | ||||
| Hypertension | 5 (45.5) | 1 (25.0) | 4 (57.1) | .55 |
| Cardiovascular disease | 2 (18.2) | 0 (0.0) | 2 (28.6) | .49 |
| Diabetes | 1 (9.0) | 0 (0.0) | 1 (14.3) | 1 |
| SARS-CoV-2 test | ||||
| Viral load (log10 copies/μL) of nasopharyngeal swab collected around admission, median (IQR) | 2.6 (2.1–4.9) | 1.5 (0.7–4.5) | 3.1 (2.1–4.9) | .40 |
| Presence of RNAemia on admission, n (%) | 5 (45.5) | 1 (25.0) | 4 (57.1) | .55 |
| Neutralization test of the first sample obtained on admission | ||||
| Number of patients in whom neutralization activity reached ≥ 50% even on admission, n (%) | 10 (90.9) | 4 (100.0) | 6 (85.7) | 1 |
| Median days after onset (range) | 8 (2–12) | 9 (2–12) | 6 (3–9) | .39 |
| Relative % of infectivity, mean ± SD | 28.5 ± 26.0 | 6.4 ± 3.4 | 41.1 ± 24.6 | .011 |
| Median time between neutralization tests (range) | 7 (2–22) | 3.5 (3–8) | 8 (2–22) | .21 |
| Length of hospital stay, median days (IQR) | 46 (19–51) | 20 (15.3–39.8) | 50 (22–56) | .073 |
| Treatment, n (%) | ||||
| Favipiravir | 9 (81.8) | 4 (100.0) | 5 (71.4) | .49 |
| Antibiotic therapy | 7 (63.6) | 0 (0.0) | 7 (100.0) | .0003 |
| Clinical outcomes, n (%) | ||||
| Required oxygen supplementation | 7 (63.6) | 0 (0.0) | 7 (100.0) | .003 |
| ICU admission | 6 (54.5) | 0 (0.0) | 6 (85.7) | .015 |
| Invasive mechanical ventilation | 1 (9.1) | 0 (0.0) | 1 (14.3) | 1 |
| In-hospital mortality | 1 (9.1) | 0 (0.0) | 1 (14.3) | 1 |